GU Cancers 2024 | AMBASSADOR: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma
Andrea Apolo, MD, National Institutes of Health, Bethesda, MD, discusses findings from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in patients with muscle-invasive and locally advanced urothelial carcinoma (MIUC) of the bladder, upper tract, or urethra. Patients were stratified based on PD-L1 status, whether they have received neoadjuvant chemotherapy and pathological stage. The two primary endpoints were disease-free survival (DFS) and overall survival (OS). Whilst DFS in the pembrolizumab arm was statistically significant, the co-primary endpoint of OS was not met. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)